Just some hours ago, at ASCO GI cancers 2017:
"The evidence is convincing that MSI-High patients with metastatic disease get benefit from new checkpoint inhibitors" and in fact they are an option, according with the NCC [National Comprehensive Cancer Network] guidelines.
"We check for MSI status inmmediatly in patients with metastatic disease"
"If I had metastatic colon cancer with MSI-High, I might prefer a checkpoint inhibitor upfront".
Alan P. Venook, MD of the University of California San Francisco, describes which colorectal patients will benefit the most from immunotherapy at the present.
http://www.oncologytube.com/video/which ... y/10000608
ASCO GI2017
01/21/17
This is a recording: find out your microsatellite status (MSS or MSI)... beep...